Neurocrine Biosciences (NASDAQ:NBIX) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report sent to investors on Monday morning,Benzinga reports.

A number of other equities research analysts also recently weighed in on the company. Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. BMO Capital Markets reduced their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Trading Down 2.1 %

NASDAQ NBIX opened at $122.88 on Monday. The firm’s 50 day simple moving average is $118.53 and its 200 day simple moving average is $132.88. The firm has a market capitalization of $12.44 billion, a price-to-earnings ratio of 32.94 and a beta of 0.35. Neurocrine Biosciences has a 1 year low of $107.84 and a 1 year high of $157.98.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC lifted its stake in Neurocrine Biosciences by 3.1% in the first quarter. Janney Montgomery Scott LLC now owns 8,907 shares of the company’s stock valued at $1,228,000 after buying an additional 270 shares during the period. QRG Capital Management Inc. boosted its stake in Neurocrine Biosciences by 9.3% during the first quarter. QRG Capital Management Inc. now owns 15,878 shares of the company’s stock worth $2,190,000 after acquiring an additional 1,352 shares in the last quarter. ProShare Advisors LLC grew its holdings in Neurocrine Biosciences by 3.3% in the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company’s stock worth $1,631,000 after purchasing an additional 383 shares during the period. Motley Fool Asset Management LLC increased its stake in Neurocrine Biosciences by 337.9% in the first quarter. Motley Fool Asset Management LLC now owns 8,188 shares of the company’s stock valued at $1,129,000 after purchasing an additional 6,318 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Neurocrine Biosciences by 2.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 109,446 shares of the company’s stock valued at $15,095,000 after purchasing an additional 2,153 shares during the period. 92.59% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.